Skip to main content

EU vaccine row, MNB asset purchases, CBRT impresses

The risk of a large shortfall in COVID-19 vaccine deliveries to the EU threatens to delay the recovery that we had expected in Emerging Europe during the first half of this year. While the central bank of Hungary kept its main policy rates on hold this week, we think its decision to step up its asset purchase programme will be followed with a cut to short-term interest rates in the coming months. Finally, the Turkish central bank’s Inflation Report provided a (rare) realistic assessment of the outlook and offers further evidence that the shift to orthodoxy will stick.

Subscriber content

Read this in full, free

Start a free trial and use one of your 10 free starter credits to unlock this piece.


Free. 10 articles. No card required.

By completing this form you are agreeing to our Terms and Conditions for the provision of a free trial of Capital Economics' services. We take your privacy seriously and will not share your details with others without your consent. By providing your details, including your email address, you are consenting to Capital Economics sending you macroeconomic commentary and analysis. You can unsubscribe at any time. See our Privacy Policy for more information.